Search results

1291 results

Sorted by Relevance . Sort by Date

  1. Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

    Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

  2. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

    Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

  3. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

  4. Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

    Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease

  5. Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

    Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib

  6. Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)

    Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults

  7. Tofacitinib for moderately to severely active ulcerative colitis (TA547)

    Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults

  8. Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

    Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

  9. Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

    Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

  10. Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

    Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)

  11. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

  12. Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

    Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults

  13. Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

    Evidence-based recommendations on ciclosporin (Ikervis) for treating dry eye disease that has not improved despite treatment with artificial tears

  14. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for treating previously untreated mantle cell lymphoma in adults

  15. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept, adalimumab, etanercept and tocilizumab for treating polyarticular juvenile idiopathic arthritis (JIA)

  16. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab…

  17. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza)

  18. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

  19. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

    Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

  20. Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)

    Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years)

  21. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

    Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C

  22. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants Gliadel) and temozolomide (Temodal) for newly diagnosed high-grade glioma (brain tumour)

  23. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults

  24. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease (ADPKD)

  25. Idelalisib for treating chronic lymphocytic leukaemia (TA359)

    Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults

  26. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

  27. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...

  28. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism

  29. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

  30. Everolimus for preventing organ rejection in liver transplantation (TA348)

    Evidence-based recommendations on everolimus (Certican) for preventing organ rejection in people having a liver transplant

  31. Dexamethasone intravitreal implant for treating diabetic macular oedema (TA349)

    Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating diabetic macular oedema

  32. Secukinumab for treating moderate to severe plaque psoriasis (TA350)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating moderate to severe plaque psoriasis

  33. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction (TA52)

    Evidence-based recommendations on streptokinase (Streptase), alteplase (Actilyse), reteplase (Rapilysin) and tenecteplase (Metalyse) for early thrombolysis in

  34. Guidance on the use of ultrasound locating devices for placing central venous catheters (TA49)

    Evidence-based recommendations on ultrasound locating devices for placing central venous catheters into the internal jugular vein